This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Abaxis Falls After Downgrade On Piccolo Revenue

NEW YORK (AP) ¿ Shares of blood analysis systems company Abaxis Inc. fell Tuesday after a SunTrust Robinson Humphrey analyst downgraded the stock, pointing to weak sales of Abaxis' Piccolo xpress testing device.

Analyst Jonathan Block said sales of Piccolo systems "dropped precipitously" this year after Abaxis instituted a new sales strategy, and the company will probably need to close some large deals to reach Wall Street's expectations. If that does not happen, the stock price could drop, he said.

Block cut his rating on shares of the Union City, Calif., company to "Neutral" from "Buy," and trimmed his fiscal 2010 and 2011 profit estimates. He now expects the company to earn 70 cents per share for the year ending in March, down from 71 cents per share, and 90 cents per share the following year, down from 92 cents per share.

On average, Thomson Reuters says analysts expect 71 cents per share in 2010 and 89 cents per share in 2011. In morning trading, Abaxis stock slid $1.18, or 4.6 percent, to $24.41.

Block said Abaxis' new veterinary products are selling well, and so are its chemistry analyzer products. However he said the stock price will not rise further until sales of the medical products improve.

Abaxis shares have climbed 62 percent over the last year, and peaked at $29.80 on Sept. 17.
Copyright 2009 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ABAX $45.66 2.20%
AAPL $93.56 -1.30%
FB $116.84 0.09%
GOOG $694.89 0.56%
TSLA $237.78 -4.00%


Chart of I:DJI
DOW 17,807.54 +33.90 0.19%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs